
EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium ...
On Tuesday, Alzamend Neuro, Inc. ALZN announced its plans to initiate a phase 2 clinical study of AL001 for patients with post-traumatic stress disorder (PTSD) in the fourth quarter of 2025. The study follows Tesla Dynamic Coils BV's completion of a …